← All trials
NCT04284774
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 20, 2020
- Primary completion
- Sep 30, 2027
- Completion date
- Sep 30, 2027
- First posted
- Feb 26, 2020
- Last posted
- Feb 26, 2020
- Enrollment
- 49
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Cancer Institute (NCI)Lead sponsor
- National Cancer Institute (NCI)Overall official - principal investigator
Drugs studied
Indications studied
- Brain Neoplasms
- Ependymoma
- Glioma
- Histiocytosis, Langerhans-Cell
- Kidney Diseases
- Lymphoma, Non-Hodgkin
- Medulloblastoma
- Melanoma
- Neoplasms
- Neoplasms, Germ Cell and Embryonal
- Wilms Tumor
- Neuroblastoma
- Pheochromocytoma
- Rhabdomyosarcoma
- Sarcoma
- Sarcoma, Ewing
- Osteosarcoma
- Thyroid Neoplasms
- Neuroectodermal Tumors
- Hepatoblastoma
- Rhabdoid Tumor
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.